{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:12:43Z","timestamp":1789535563778,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:00:00Z","timestamp":1468281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:00:00Z","timestamp":1468281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA097397"],"award-info":[{"award-number":["CA097397"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA114236"],"award-info":[{"award-number":["CA114236"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Scientific Committee of the Danish Cancer Society","award":["R90-A5792-14-S2"],"award-info":[{"award-number":["R90-A5792-14-S2"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA008748"],"award-info":[{"award-number":["CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13058-016-0726-0","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T03:35:09Z","timestamp":1466652909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study"],"prefix":"10.1186","volume":"18","author":[{"name":"the WECARE Study Collaborative Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Langballe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Mellemkj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther M.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Concannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonine L.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,12]]},"reference":[{"issue":"9472","key":"726_CR1","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group\u00a0(EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group\u00a0(EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687\u2013717.","journal-title":"Lancet."},{"issue":"9793","key":"726_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Early Breast Cancer Trialists' Collaborative Group\u00a0(EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771\u201384. doi:\n                    10.1016\/S0140-6736(11)60993-8\n                    \n                  .","journal-title":"Lancet"},{"issue":"18","key":"726_CR3","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/jnci\/87.18.1359","volume":"87","author":"LS Cook","year":"1995","unstructured":"Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst. 1995;87(18):1359\u201364.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"726_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-007-9709-2","volume":"110","author":"M Schaapveld","year":"2008","unstructured":"Schaapveld M, Visser O, Louwman WJ, Willemse PH, de Vries EG, van der Graaf WT, et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008;110(1):189\u201397.","journal-title":"Breast Cancer Res Treat"},{"issue":"34","key":"726_CR5","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.2007.16.0192","volume":"26","author":"MJ Hooning","year":"2008","unstructured":"Hooning MJ, Aleman BM, Hauptmann M, Baaijens MH, Klijn JG, Noyon R, et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol. 2008;26(34):5561\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"726_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/jnci\/djm267","volume":"100","author":"L Bertelsen","year":"2008","unstructured":"Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2008;100(1):32\u201340.","journal-title":"J Natl Cancer Inst"},{"issue":"28","key":"726_CR7","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1200\/JCO.2011.39.3645","volume":"30","author":"V Vichapat","year":"2012","unstructured":"Vichapat V, Garmo H, Holmqvist M, Liljegren G, Warnberg F, Lambe M, et al. Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. J Clin Oncol. 2012;30(28):3478\u201385.","journal-title":"J Clin Oncol"},{"issue":"3","key":"726_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1023\/A:1006117220284","volume":"53","author":"PA Newcomb","year":"1999","unstructured":"Newcomb PA, Solomon C, White E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat. 1999;53(3):271\u20137.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"726_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.annepidem.2014.08.003","volume":"24","author":"L Mellemkjaer","year":"2014","unstructured":"Mellemkjaer L, Steding-Jessen M, Frederiksen K, Andersson M, Ejlertsen B, Jensen MB, et al. Risk of contralateral breast cancer after tamoxifen use among Danish women. Ann Epidemiol. 2014;24(11):843\u20138. doi:\n                    10.1016\/j.annepidem.2014.08.003\n                    \n                  .","journal-title":"Ann Epidemiol"},{"issue":"17","key":"726_CR10","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1158\/0008-5472.CAN-09-1355","volume":"69","author":"CI Li","year":"2009","unstructured":"Li CI, Daling JR, Porter PL, Tang MT, Malone KE. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res. 2009;69(17):6865\u201370.","journal-title":"Cancer Res"},{"key":"726_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-015-0619-6","author":"L Xu","year":"2015","unstructured":"Xu L, Zhao Y, Chen Z, Wang Y, Chen L, Wang S. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis. Breast Cancer. 2015. doi:\n                    10.1007\/s12282-015-0619-6\n                    \n                  .","journal-title":"Breast Cancer"},{"issue":"2","key":"726_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-010-0769-3","volume":"123","author":"KW Reding","year":"2010","unstructured":"Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, et al. Adjuvant systemic therapy for breast cancer in BRCA1\/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat. 2010;123(2):491\u20138. doi:\n                    10.1007\/s10549-010-0769-3\n                    \n                  .","journal-title":"Breast Cancer Res Treat"},{"issue":"9245","key":"726_CR13","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","volume":"356","author":"SA Narod","year":"2000","unstructured":"Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356(9245):1876\u201381.","journal-title":"Lancet"},{"issue":"9114","key":"726_CR14","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451\u201367.","journal-title":"Lancet."},{"issue":"6","key":"726_CR15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1072-7515(99)00057-5","volume":"188","author":"R O'Regan","year":"1999","unstructured":"O'Regan R, Jordan VC, Gradishar WJ. Tamoxifen and contralateral breast cancer. J Am Coll Surg. 1999;188(6):678\u201383.","journal-title":"J Am Coll Surg"},{"issue":"21","key":"726_CR16","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","volume":"32","author":"HJ Burstein","year":"2014","unstructured":"Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255\u201369. doi:\n                    10.1200\/JCO.2013.54.2258\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"1","key":"726_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67\u201375. doi:\n                    10.1016\/S1470-2045(14)71171-4\n                    \n                  .","journal-title":"Lancet Oncol"},{"issue":"7","key":"726_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnci\/djh097","volume":"96","author":"SM Swain","year":"2004","unstructured":"Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst. 2004;96(7):516\u201323.","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"726_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/jnci\/93.13.1008","volume":"93","author":"CI Li","year":"2001","unstructured":"Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst. 2001;93(13):1008\u201313.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"726_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10549-010-1137-z","volume":"127","author":"C Bouchardy","year":"2011","unstructured":"Bouchardy C, Benhamou S, Fioretta G, Verkooijen HM, Chappuis PO, Neyroud-Caspar I, et al. Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat. 2011;127(1):233\u201341.","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"726_CR21","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/jnci\/djg060","volume":"95","author":"JJ Dignam","year":"2003","unstructured":"Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst. 2003;95(19):1467\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"726_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/BF00052945","volume":"7","author":"LS Cook","year":"1996","unstructured":"Cook LS, White E, Schwartz SM, McKnight B, Daling JR, Weiss NS. A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Causes Control. 1996;7(3):382\u201390.","journal-title":"Cancer Causes Control"},{"issue":"9814","key":"726_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Early Breast Cancer Trialists' Collaborative Group\u00a0(EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432\u201344. doi:\n                    10.1016\/S0140-6736(11)61625-5\n                    \n                  .","journal-title":"Lancet"},{"issue":"10001","key":"726_CR24","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"M Dowsett","year":"2015","unstructured":"Early Breast Cancer Trialists' Collaborative Group\u00a0(EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341\u201352. doi:\n                    10.1016\/S0140-6736(15)61074-1\n                    \n                  .","journal-title":"Lancet"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-016-0726-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-016-0726-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-016-0726-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-016-0726-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T09:09:32Z","timestamp":1589533772000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-016-0726-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,12]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1186\/s13058-016-0726-0","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,12]]},"assertion":[{"value":"15 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"65"}}